Data that was presented at the American Urological Association (AUA) Annual Meeting (4–8 May, San Deigo, USA) demonstrated that treatment for benign prostatic hyperplasia with GreenLight XPS laser therapy with MoXy fibre (American Medical Systems), instead of transurethral resection of the prostate (TURP), resulted in significantly shorter hospitalisation, catheterisation, and recovery times for patients, while maintaining equivalent safety and efficacy.
Women who had sufficient amounts of vitamin D were 32 percent less likely to develop fibroids than women with insufficient vitamin D, according to a study from researchers at the National Institutes of Health.
The National Institutes of Health is looking for volunteers to take part in a study to compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes. Beginning recruitment in June, the project is called the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study.
St. Jude Medical, Inc. (St. Paul, MN) announced US Food and Drug Administration (FDA) approval to begin the EnligHTN IV renal denervation study, the first United States trial using the EnligHTN multielectrode renal denervation system to treat patients with drug-resistant high blood pressure.
NeoTract announced the successful results of the 206-patient LIFT investigational device exemption study, a multicentre randomised, blinded study in patients with benign prostatic hyperplasia.
Boston Scientific Corporation (BSX) continues to demonstrate its commitment to women s health by providing a research and education grant of more than $1 million to the Pelvic Floor Disorders Network (PFDN) for the SUPeR clinical trial. The SUPeR study will evaluate treatment outcomes of two different surgical options for women with uterine prolapse, a form of pelvic organ prolapse.
Medtronic announced on 4 June 2013 that the Pacific Plus percutaneous transluminal angioplasty (PTA) catheter has received both FDA clearance and the CE mark. The launch of the new peripheral balloon catheter is underway in the United States and internationally.
Las dietas reducidas en carbohidratos, grasas y el régimen alimentario mediterráneo serían igualmente beneficiosos para las personas con sobrepeso y enfermedad renal leve o moderada. Incluso la dieta con bajo contenido de carbohidratos, que es más rica en proteínas, "es aparentemente tan efectiva como las dietas mediterránea o reducidas en grasa para mejorar la función renal, lo que ocurriría con las tres dietas por la disminución de la presión y el aumento de la sensibilidad a la insulina que ocurre al adelgazar", explicó la doctora Iris Shai por e-mail.
Teleflex Incorporated (TFX), a leading global provider of medical devices for critical care and surgery, has announced that its subsidiary Hotspur Technologies, Inc., which Teleflex acquired in June 2012, completed CE marking requirements to market the company’s Arrow® GPSCath® Balloon Dilatation Catheters to the European Union. These novel products enable multiple vascular procedures to be performed with one dual-function catheter, potentially reducing procedure time and expense for both patients and medical professionals.
Biosensors International Group, Ltd. (Singapore) has entered into a licensing agreement with Eurocor GmbH, a group company of Opto Circuits (India) Ltd. (Karnakata, India), for their drug-eluting balloon (DEB) technology and related intellectual property rights in relation to the treatment of both coronary and peripheral artery disease. As a first step in this process, an original equipment manufacturer arrangement is being implemented, whereby Biosensors will market and sell, under its own brand, DEBs manufactured by Eurocor. Both agreements will involve three Biosensors-branded DEBs: BioStream, BioPath 014, and BioPath 035.
Twelve-month results from the ILLUMENATE First-in-Human Study on the safety and effectiveness of Covidien’s drug-eluting balloon were presented at the EuroPCR congress in Paris, France. The new platform features a paclitaxel-coated angioplasty balloon with a proprietary, rapid-release drug delivery mechanism
Data from the WAVE I study, presented at a late-breaking trial session at EuroPCR (21-24 May, Paris, France), showed that patients treated with Kona Medical’s Surround Sound renal denervation system had no device-related serious adverse events, and experienced a 22mmHg drop in systolic blood pressure and a 9mmHg drop in diastolic blood pressure at three months (N=24) - See more at: http://www.cxvascular.com/cn-latest-news/cardiovascular-news---latest-news/three--and-six-month-data-for-surround-sound-renal-denervation-system-presented-at-europcr#sthash.LlJILubO.dpuf
Open access publisher BioMed Central has announced the launch of the Journal of Therapeutic Ultrasound in partnership with the Focused Ultrasound Foundation and the International Society for Therapeutic Ultrasound.
Una encuesta revela que los tranquilizantes conocidos como benzodiacepinas y otros antidepresivos más antiguos están relacionados con un mayor riesgo de padecer disfunción eréctil (DE). "Definitivamente, esto confirma que los tricíclicos (antidepresivos)" están asociados con la DE, dijo el doctor Richard Balon, profesor de psiquiatría de la Facultad de Medicina de Wayne State University.
Boston Scientific Corporation (Natick, MA) announced that interim data from the REDUCE-HTN clinical program were presented at EuroPCR 2013 in Paris by Joachim Schofer, MD, of the Hamburg University Cardiovascular Center in Hamburg, Germany.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos